National Bank of Canada
CAPR icon

National Bank of Canada’s Capricor Therapeutics CAPR Stock Holding History

National Bank of Canada’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,147
Closed -$1.14M – 2891
2025
Q2 		$1.14M Buy
+1,147
New +$12.1K ﹤0.01% 1249

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
PC
Pier Capital Stamford, Connecticut $755M AUM 94.38% 1-Year Est. Return
Swiss National Bank
Swiss National Bank Zurich, Switzerland $191B AUM 45.21% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
BDF
Black Diamond Financial Towson, Maryland $1.13B AUM 22.3% 1-Year Est. Return
OC
Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return

National Bank of Canada's CAPR Position: Q2 2026 in Review

National Bank of Canada opened a new position in Capricor Therapeutics (CAPR) in Q2 2026: 11 shares worth $265. The stake represents ﹤0.01% of the portfolio and ranks #2936 among its holdings. This is a return to the name: National Bank of Canada previously reported a position in CAPR as recently as Q4 2025.

National Bank of Canada first reported a position in CAPR in Q2 2025 and has held it in 4 quarters since. The position peaked at $4.14M in Q4 2025. 59 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • National Bank of Canada held 11 shares of Capricor Therapeutics worth $265 as of Q2 2026.
  • Capricor Therapeutics was a new National Bank of Canada position in Q2 2026.
  • Capricor Therapeutics made up ﹤0.01% of National Bank of Canada's portfolio in Q2 2026, its #2936 holding.
  • National Bank of Canada first reported a position in Capricor Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • National Bank of Canada's Capricor Therapeutics position peaked at $4.14M in Q4 2025.
  • 59 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on National Bank of Canada's 13F filing for Q2 2026, filed 10 Aug 2026.